Abstract
The anthracycline doxorubicin (DOX) is widely used in chemotherapy due to its efficacy in fighting a wide range of cancers such as carcinomas, sarcomas and hematological cancers. Despite extensive clinical utilization, the mechanisms of action of DOX remain under intense debate. A growing body of evidence supports the view that this drug can be a double-edge sword. Indeed, injury to nontargeted tissues often complicates cancer treatment by limiting therapeutic dosages of DOX and diminishing the quality of patients life during and after DOX treatment. The literature shows that the heart is a preferential target of DOX toxicity. However, this anticancer drug also affects other organs like the brain, kidney and liver. This review is mainly devoted to discuss the mechanisms underlying not only DOX beneficial effects but also its toxic outcomes. Additionally, clinical studies focusing the therapeutic efficacy and side effects of DOX treatment will be discussed. Finally, some potential strategies to attenuate DOX-induced toxicity will be debated.
Keywords: Brain, doxorubicin, heart, kidney, liver, therapeutic effects, side effects
Current Medicinal Chemistry
Title: Doxorubicin: The Good, the Bad and the Ugly Effect
Volume: 16 Issue: 25
Author(s): Cristina Carvalho, Renato X. Santos, Susana Cardoso, Sonia Correia, Paulo J. Oliveira, Maria S. Santos and Paula I. Moreira
Affiliation:
Keywords: Brain, doxorubicin, heart, kidney, liver, therapeutic effects, side effects
Abstract: The anthracycline doxorubicin (DOX) is widely used in chemotherapy due to its efficacy in fighting a wide range of cancers such as carcinomas, sarcomas and hematological cancers. Despite extensive clinical utilization, the mechanisms of action of DOX remain under intense debate. A growing body of evidence supports the view that this drug can be a double-edge sword. Indeed, injury to nontargeted tissues often complicates cancer treatment by limiting therapeutic dosages of DOX and diminishing the quality of patients life during and after DOX treatment. The literature shows that the heart is a preferential target of DOX toxicity. However, this anticancer drug also affects other organs like the brain, kidney and liver. This review is mainly devoted to discuss the mechanisms underlying not only DOX beneficial effects but also its toxic outcomes. Additionally, clinical studies focusing the therapeutic efficacy and side effects of DOX treatment will be discussed. Finally, some potential strategies to attenuate DOX-induced toxicity will be debated.
Export Options
About this article
Cite this article as:
Carvalho Cristina, Santos X. Renato, Cardoso Susana, Correia Sonia, Oliveira J. Paulo, Santos S. Maria and Moreira I. Paula, Doxorubicin: The Good, the Bad and the Ugly Effect, Current Medicinal Chemistry 2009; 16 (25) . https://dx.doi.org/10.2174/092986709788803312
DOI https://dx.doi.org/10.2174/092986709788803312 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Cytochrome P450 Structure, Function and Clinical Significance: A Review
Current Drug Targets Wide-Ranging Genomic Effects of Plasticisers and Related Compounds
Current Drug Metabolism Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition Apoptosis and Arrays: Identifying a Transcription Component of Programmed Cell Death
Current Genomics Oxidative Stress in Tumor Angiogenesis - Therapeutic Targets
Current Pharmaceutical Design Developments in the Application of 1,2,3-Triazoles in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Molecular Pathology in Neurodegenerative Diseases
Current Drug Targets Synthesis and Cytotoxic Activity of New β-Carboline Derivatives
Mini-Reviews in Medicinal Chemistry Effects of Diet-Derived Molecules on the Tumor Microenvironment
Current Angiogenesis (Discontinued) Contribution of Specific Transport Systems to Anthracycline Transport in Tumor and Normal Cells
Current Drug Metabolism Nanoemulsion Encapsulation and In Vitro SLN Models of Delivery for Cytotoxic Methotrexate
Current Drug Discovery Technologies Kinases as Upstream Regulators of the HIF System: Their Emerging Potential as Anti-Cancer Drug Targets
Current Pharmaceutical Design Receptor Tyrosine Kinase Kit and Gastrointestinal Stromal Tumours: An Overview
Current Medicinal Chemistry Lentiviral Vectors for Gene Therapy of HIV-1 Infection
Current Gene Therapy Synthesis and Biological Evaluation of Novel Antifolate Analogs as Potential Anticancer Treatment
Anti-Cancer Agents in Medicinal Chemistry PET Imaging for Gene & Cell Therapy
Current Gene Therapy New Therapeutic Property of Dimebon as a Neuroprotective Agent
Current Medicinal Chemistry Alteration of the Proline at Position 7 of the HIV-1 Spacer Peptide p1 Suppresses Viral Infectivity in a Strain Dependent Manner
Current HIV Research The mAP-KL Algorithm Combined with Mutual Information Network Used to Screen Hub Genes in Osteosarcoma
Current Bioinformatics